Thanks for the detailed answer. If I understood correctly, in this forecast, generic enzalutamide slows down Nubeqa’s growth, but the increase in patient numbers and new indications compensate for the price pressure in the years 2027–2030.
Does the forecast include a separate assumption for the decline in Nubeqa’s net price, or does the effect of generic enzalutamide appear only as slower revenue growth?
In other words, is the correct interpretation that at the target price of 83 euros, Nubeqa’s sales are assumed to grow every year despite generic enzalutamide?